Company: BioNTech SE
Ticker: NASDAQ: BNTX
Price: $83.89
Change: -$18.27
% Change: -17.884%

Shares of BioNTech SE (NASDAQ: BNTX) slumped sharply, making the stock one of the biggest decliners among U.S.-listed names. The selloff came as investors reacted to a softer-than-expected 2026 revenue outlook and a leadership transition announcement involving co-founders Ugur Sahin and Özlem Türeci. Barron’s also reported that the weak 2026 outlook was a central reason for the decline.

Company Overview

BioNTech is best known for its COVID-19 vaccine partnership with Pfizer, but its strategic identity has shifted decisively toward oncology. The company now describes itself as an immunotherapy and biotechnology business focused on mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, including antibody-drug conjugates and cell therapies. Its pipeline spans multiple late-stage oncology assets, with particular emphasis on pumitamig, a PD-L1/VEGF-A bispecific being advanced with Bristol Myers Squibb, as well as additional mRNA cancer immunotherapy programs.

This strategic repositioning matters because the market is no longer valuing BioNTech as a pandemic-windfall vaccine story alone. Investors are increasingly judging the company on whether it can convert its substantial cash pile and deep pipeline into a durable multi-product oncology business over time. Management said 2026 should be a “pivotal year,” with multiple readouts expected across its portfolio.

Financial Performance

BioNTech reported full-year 2025 revenue of €2.87 billion, compared with €2.75 billion in 2024, helped by collaboration revenue from Bristol Myers Squibb recognized in the third quarter. But profitability moved further into the red: the company posted a full-year net loss of €1.14 billion and a diluted loss per share of €4.70, versus a €665.3 million net loss and €2.77 diluted loss per share in 2024. For the fourth quarter of 2025, revenue was €907.4 million, down from €1.19 billion a year earlier, mainly due to lower COVID-19 vaccine sales.

The balance sheet remains a major strength. BioNTech ended 2025 with €17.2 billion in cash, cash equivalents, and security investments, giving it significant flexibility to fund late-stage trials, business development, and commercialization buildout. That cash buffer is one reason the stock remains strategically important even as earnings stay under pressure.

Reason Behind the Selloff

The main trigger was guidance. BioNTech said it expects 2026 revenue of €2.0 billion to €2.3 billion, with adjusted R&D expense of €2.2 billion to €2.5 billion and adjusted SG&A of €700 million to €800 million. MarketBeat noted that the 2026 revenue outlook was below consensus, and Barron’s reported that investors also reacted negatively to the founders’ planned departure to start a new mRNA-focused venture.

In other words, the market appears to be discounting three things at once: shrinking COVID vaccine contribution, a heavy oncology investment cycle, and added uncertainty from leadership succession. None of those necessarily undermine the long-term thesis, but together they make 2026 look like another transition year rather than an earnings recovery year. That tends to compress multiples in biotech, especially after a strong pre-existing cash-and-pipeline premium.

Management Outlook and Guidance

Management framed 2026 as a catalyst-heavy year. The company said it expects six late-stage data readouts in 2026 and plans to have eight global Phase 3 pumitamig trials ongoing by year-end. CEO Ugur Sahin said 2025 brought “strong execution and pipeline momentum,” and that 2026 should be a significant step toward becoming a multi-product company by 2030.

That forward view is strategically encouraging, but the market’s issue is timing. BioNTech is spending aggressively now to build future oncology optionality, while 2026 revenues are still anchored by a declining vaccine franchise and no material oncology product revenue contribution. So management’s outlook is ambitious scientifically, but financially it still implies a period of negative operating leverage.

Technical Insights

From a chart perspective, the drop to $83.89 represents a decisive breakdown in near-term sentiment. The stock has now moved far below the psychologically important $100 area referenced in recent trading history, with Marketscreener showing BNTX at $100.76 on March 3, 2026 before the earnings-driven selloff.

Key levels to watch:

Support: $80 / $75
Resistance: $90 / $100

A failure to hold the $80 zone could invite further de-risking, while any recovery likely needs a move back above $90 first. Because BioNTech is fundamentally event-driven now, future technical direction will probably depend on pipeline data, commercial clarity, and how investors digest the management transition.

Conclusion

The sharp fall in BioNTech SE (NASDAQ: BNTX) reflects a market reset around near-term expectations rather than a collapse in the company’s strategic relevance. BioNTech still has one of the strongest balance sheets in biotech, a broad late-stage oncology pipeline, and a clear long-term goal of becoming a multi-product cancer franchise.

What investors disliked was the combination of weaker-than-expected 2026 revenue guidance, continued high spending, and leadership transition news. Until the company begins converting pipeline progress into clearer commercial visibility, the stock may remain volatile. Still, for longer-term investors, BioNTech now looks increasingly like a high-cash oncology platform rather than a fading COVID-vaccine story alone.